Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Able to give written informed consent prior to participation in the study~* At least 12 years of age at visit 1 and a minimum weight of 45 kilogram (kg)~* A well-documented requirement for regular treatment with high dose inhaled corticosteroid (ICS) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids (OCS)~* Current treatment with an additional controller medication, besides ICS, for at least 3 months or a documented failure in the past 12 months of an additional controller medication for at least 3 successive months~* Prior documentation of eosinophilic asthma or high likelihood of eosinophilic asthma~* At Visit 1, a pre-bronchodilator FEV1 \<80% (for subjects \>= 18 years of age), a pre-bronchodilator FEV1 \<90% or FEV1:FVC ratio \<0.8 (for subjects 12-17 years of age).~* Previously confirmed history of two or more exacerbations requiring treatment with systemic CS~* Male or Eligible Female (females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control)~* French subjects will be included only if either affiliated to or a beneficiary of a social security category.~Exclusion Criteria:~* Current smokers or former smokers with a smoking history of \>=10 pack years~* Presence of a known pre-existing, clinically important lung condition other than asthma~* A current malignancy or previous history of malignancy in less than 12 months~* Known, pre-existing, unstable liver disease cirrhosis and known biliary abnormalities~* Known, pre-existing severe or clinically significant cardiovascular disease~* known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment~* Subjects with any eosinophilic diseases~* QTc(F) ≥450msec or QTc(F) ≥480 msec~* A history of alcohol/substance abuse~* Subject with known immunodeficiency~* Subjects who have received omalizumab within 130 days of Visit 1 or any monoclonal antibody (other than Xolair) to treat inflammatory disease within 5 half-lives of Visit 1~* Subjects who have received treatment with an investigational drug within the past 30 days or five terminal phase half-lives of the drug whichever is longer~* Subjects with allergy/intolerance to a monoclonal antibody or biologic.~* Subjects who are pregnant or breastfeeding~* Subjects who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations~* Previously participated in any study with mepolizumab and received investigational product (including placebo)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mepolizumab IV (Type: EXPERIMENTAL): Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
- Mepolizumab SC (Type: EXPERIMENTAL): Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).